ClinicalTrials.gg
CompletedNCT05373732Updated May 13, 2022

Stress Reduction in the Prevention of Left Ventricular Hypertrophy

An interventional study of meditation and Health education control in Left Ventricular Hypertrophy and High Blood Pressure, sponsored by Maharishi International University. Completed. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-05-13.

Sponsored by Maharishi International University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 26 years after the study started (first participant enrolled Apr 1996, registered Apr 2022).
Phase
Not applicable
Study type
Interventional
Enrollment
171
Allocation
Randomized
Ages
20 Years to 75 Years
Sex
All
01

Study summary

This study evaluated the effect of stress reduction by Transcendental Meditation (TM) on left ventricular mass compared to a health education control group in pre-hypertensive or hypertensive African-American adults over a six-month intervention period.

Read the detailed description

Left ventricular hypertrophy (LVH) is an independent risk factor for cardiovascular disease (CVD). African Americans have higher rates of LVH and CVD than whites. Substantial evidence indicates that psychological stress contributes to LVH. This randomized controlled trial evaluated the effect of stress reduction with the Transcendental Meditation (TM) technique on left ventricular mass (LVM) in hypertensive African-Americans.

Hypertensive African American men and women were tested at baseline for left ventricular mass index (LVMI) by M-mode echocardiography, blood pressure, lifestyle and behavioral factors. Subjects were randomly assigned to either TM or health education (HE) control. After six months intervention, 86 subjects were posttested on all outcomes. Data were analyzed for between-group and within-group differences.

02

Conditions studied

  • Left Ventricular Hypertrophy
  • High Blood Pressure

Keywords

  • left ventricular mass
  • meditation
  • stress reduction
03

In context

Hypertrophy, Left Ventricular

162 studies on the registry are indexed under Hypertrophy, Left Ventricular; 28 are open to participants now.

This study's enrollment of 171 is above the median of 100 across 97 interventional studies indexed under Hypertrophy, Left Ventricular.

Browse Hypertrophy, Left Ventricular studies →

Lead sponsor

Maharishi International University is the lead sponsor of 16 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: self-identified African-American men and women ages, 20-75 years old, with either prehypertension (systolic blood pressure (SBP) of 120-139 mm Hg and/or diastolic blood pressure (DBP) of 80-89 mm Hg), Stage-1 hypertension (SBP of 140-159 mm Hg and/or DBP of 90-99 mm Hg) or Stage-2 hypertension (SBP of 160-179 and/or DBP of 100-109 mm of Hg), with or without antihypertensive medications -

Exclusion Criteria: Patients with a history of stroke, transient cerebral ischemic attack, congestive heart failure, myocardial infarction, angina pectoris or with significant abnormalities, major psychiatric or behavioral disorder such as alcoholism (> 28 drinks per week)

-

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Care provider, Investigator, Outcomes assessor)
Enrollment
171 participants (actual)

Study arms

  • Experimental
    Transcendental Meditation

    The Transcendental Meditation (TM) technique is described as a simple, natural technique that is practiced twice a day for 20 minutes while sitting comfortably with eyes closed. There are no required changes in lifestyle, beliefs or philosophy. Instruction in the TM technique involves a seven-step course over five sessions (90-minute meetings).

    Behavioral: meditation

  • Active comparator
    Health Education

    The health education (HE) intervention provided behavioral instructions for CVD risk factor prevention . This group received written materials, structured presentations, didactic instructions and group support for modifying the major cardiovascular risk factors including salt restriction, weight reduction, aerobic exercise, alcohol and smoking cessation.

    Behavioral: Health education control

Interventions

  • Behavioralmeditation

    meditation practice 20 minutes twice a day at home and attending classes at the clinic.

    Also known as: stress reduction

  • BehavioralHealth education control

    didactic based classes in CVD risk factor reduction and prevention

06

What researchers measure

Primary outcomes

  1. left ventricular mass (LVM)

    The primary outcome was change in LVMI. LVM was measured by M-mode echocardiography and indexed by body surface area to generate LVMI. \[18\] Measurements were obtained at the end-diastole. Interventricular septal thickness, posterior wall thickness, and left ventricle internal dimension were measured.

    Time frame: 6 months pre to post

Secondary outcomes

  1. blood pressure

    systolic and diastolic blood pressure

    Time frame: 0 and 6 months

  2. anger expression

    Speilberger Anger expression scale

    Time frame: 0 and 6 months

  3. perceived stress

    Perceived Stress Scale, a 5-item subset of the California Self-Evaluation Scale to measure self-esteem, and a personal efficacy scale

    Time frame: 0 and 6 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Schneider RH, Myers HF, Marwaha K, Rainforth MA, Salerno JW, Nidich SI, Gaylord-King C, Alexander CN, Norris KC. Stress Reduction in the Prevention of Left Ventricular Hypertrophy: A Randomized Controlled Trial of Transcendental Meditation and Health Education in Hypertensive African Americans. Ethn Dis. 2019 Oct 17;29(4):577-586. doi: 10.18865/ed.29.4.577. eCollection 2019 Fall. PubMed 31641325 ↗

Individual participant data

Plan to share: Yes — IPD is available on request to authors from other study investigators. Database on Excel is available to be emailed to inquiring investigators

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: currently available

Access criteria: contact investigators and request access to database and submit short study proposal

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 1996 to primary completion in Oct 1998, 30 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 6, 2022
First posted
May 13, 2022
StartActual
Apr 1996
Primary completionActual
Oct 1998
CompletionActual
Dec 1998
Last update
May 13, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 13, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05373732
Lead sponsor
Maharishi International University
Collaborators
Charles Drew University of Medicine and Science
Responsible party
Robert Schneider, MD (Director and Dean, Maharishi International University) — Principal investigator
First posted
May 13, 2022
Start date
Apr 1996
Primary completion
Oct 1998
Completion
Dec 1998
Last update
May 13, 2022

Study contacts

Robert H Schneider, M.D.
principal investigator · Maharishi International University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion